alexa Lost In Translation? Progress In Immunotherapy For Type 1 Diabetes
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Mark R Rigby
ScientificTracks Abstracts: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.026
Although Type 1 diabetes mellitus is clinically considered an endocrine disorder and patients require insulin supplementation for survival, it is at its origin an autoimmune disorder. Research over the past few decades indicate that a combination of the adaptive and innate immune system attacks and destroys the pancreatic beta cells ? thus rendering the body unable to produce insulin. Both cells (i.e., T cells and B cells) and soluble mediators (i.e., inflammatory cytokines) appear to have critical roles in the initiation and progression of this process. In the past, non-selective immune suppressants and immune modulators have been shown to stabilize or even reverse the disease. But as Type 1 diabetes occurs primarily in children, these harsh, nonspecific treatments cannot be adopted clinically. In the past decade there has been advancement of technology and success of novel biologic agents, such as monoclonal antibodies and fusion proteins, for other immune mediated disorders. Due to the specificity and low side effect profile of these agents, a number of trials have been undertaken using them to target specific, putative intermediates in diabetogenesis. Although many of these therapies have been very useful in other immune and inflammatory disorders, there has been limited success in Type 1 diabetes. This discussion will review the promise, progress and difficulties in using novel immune therapies in Type 1 diabetes and give a look to what?s ahead.
Mark R Rigby received his MD and PhD at the University of Massachusetts. His PhD studies focused on the immunology of Type 1 diabetes. He then conducted clinical training at Johns Hopkins University in Pediatrics and Critical Care. He is now on faculty at Indiana University. He is the national Protocol Chair of an NIH sponsored study using a drug called alefacept (LFA3-Ig) to try to reverse disease in newly diagnosed Type 1 diabetes and has been involved in many other basic and clinical research projects related to understanding the pathogenesis of and treating this condition.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

1-702-714-7001Extn: 9042

General Science

Andrea Jason

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001Extn: 9042

© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version